All News

The possibility of Brazil compulsorily licensing Abbott Laboratory’s HIV/AIDS treatment Kaletra has re-awakened the debate how the World Trade Organization’s TRIPS agreement should be interpreted for the pharma industry. We asked experts to offer different viewpoints on this issue.

Two ballot initiatives offer different methods for discounting prescription drugs in California. But what are the plans really promising? Get the details of each proposal and an analysis of efforts to sway California voters.

The trend of public/private partnerships to combat diseases of the developing world continues with collaboration between GSK and the International AIDS Vaccine Initiative. We examine the details of the deal, the science GSK plans to use and the future of this trend.

What Pharma Wants From IT Today

It's an open question whether a pharmaceutical company really needs to have the drug testing process inside its corporate walls, or whether they really should be focusing much more on building effective relationships, in terms of building awareness and acceptance of their products, with both the physicians and end consumers.

July 2005 CE.

2005 Access Report figures

If a physician wants to use protected healthcare information (PHI) for research purposes, particularly if the PHI is going to be published as part of research results, an authorization or waiver will be required.

R&D leaders face the unenviable choice of either dividing their time between science and operations, or focusing on one to the detriment of the other.

Part of the value of a drug comes from the supply chain that protects its integrity. There's a similar supply chain that preserves the value of drug information. And it needs help.

June 2005 CE.

A review of the best ads of 2004--and the people that created them.

A recently released report claims pharma hides bad clinical trial results and over-promotes drugs. Tougher regs are being called for.

Cover Story

Employees are most attracted to products they might feel guilty about buying for themselves, but when they have points to redeem, they feel fine about splurging.

TOC

Post-approval studies, at many companies, do not have a consistent strategy that builds networks of investigators.

May 2005 CE.

Conventional wisdom says that generics businesses are a drain on valuable resources. But these units are much less prone to the disastrous drug safety panics that Big Pharma has recently endured.

April 2005 CE.

Recently developed technologies produce clinical quality cells in as few as12 days. Culturing cells in petri dishes can take a month or more.

Cover Story

Johnson & Johnson's pharmaceutical group builds team and relationship skills into performance evaluations. J&J's Robert Wills says, "Such skills are a built-in expectation. It's how people are supposed to do their job. Everyone who participates in an alliance is compensated for behaviors that contribute to mutual success."

OVERVIEW

Pharma companies in Europe believe that it already takes too long for new medicines to reach patients. Separate bodies for efficacy and safety will lead to further delays.

March 2005 CE.

Pharm Exec talks to the newly appointed leaders of the industry's most influential advocacy organizations.

There's no better use of healthcare marketing dollars than to reach patients with unmet needs. That's why niche marketing has gained steam during the last few years. But increasing competition in accessing doctors who treat culturally and racially diverse patient groups means pharma marketers have to refine their definition of what constitutes a niche market in the first place. In doing so, they may stumble over a market that has not yet been saturated—US prisoners.

The LazarusEffect

The High Court ruled that Abbott should pay the agreed-on royalty of 5 percent rather than the 2 percent it's been paying. The difference may be worth $392 million